On Jan 29, 2026, SNY reported earnings of 1.53 USD per share (EPS) for Q4 25, beating the estimate of 1.46 USD, resulting in a 4.22% surprise. Revenue reached 11.30 billion, compared to an expected 11.57 billion, with a -2.31% difference. The market reacted with a +0.94% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of 1.79 USD, with revenue projected to reach 10.48 billion USD, implying an increase of 16.99% EPS, and decrease of -7.27% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pfizer Inc.
Report Date
Feb 03, 2026 For Q4 25
Estimate
$0.57
Actual
$0.66
Surprise
+14.29%
Eli Lilly & Co.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$6.73
Actual
$7.54
Surprise
+11.92%
ABBVIE INC.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$2.70
Actual
$2.71
Surprise
+0.17%
Novartis AG
Report Date
Feb 04, 2026 For Q4 25
Estimate
$2.02
Actual
$2.02
Surprise
+0.27%
Merck & Co., Inc.
Report Date
Feb 03, 2026 For Q4 25
Estimate
$2.02
Actual
$2.04
Surprise
+0.52%
Novo-Nordisk A/S
Report Date
Feb 04, 2026 For Q4 25
Estimate
$5.97
Actual
$6.32
Surprise
+5.77%
FAQ
What were Sanofi - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Sanofi - ADR reported EPS of $1.53, beating estimates by 4.22%, and revenue of $11.30B, -2.31% below expectations.
How did the market react to Sanofi - ADR's Q4 2025 earnings?
The stock price moved up 0.94%, changed from $45.77 before the earnings release to $46.20 the day after.
When is Sanofi - ADR expected to report next?
The next earning report is scheduled for Apr 23, 2026.
What are the forecasts for Sanofi - ADR's next earnings report?
Based on 4
analysts, Sanofi - ADR is expected to report EPS of $1.79 and revenue of $10.48B for Q1 2026.